Pediatric autoimmune diseases: Kawasaki disease, juvenile dermatomyositis and juvenile localized scleroderma
Christian Lood, PhD
University of Washington
Seattle, WA, United States
Disclosure(s): Amytryx: Grant/Research Support (Ongoing); Boehringer-Ingelheim: Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Grant/Research Support (Ongoing); Citryll: Consultant (Ongoing); Eli Lilly: Grant/Research Support (Ongoing); Gilead: Grant/Research Support (Ongoing); Horizon Therapeutics: Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Ongoing); Redd Pharma: Grant/Research Support (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing)
Clarissa Pilkington, MBBS, BSc, FRCPC, FRCP
Great Ormond Street Hospital
London, United Kingdom
Disclosure(s): No financial relationships with ineligible companies to disclose
Adam Schiffenbauer, MD
NATIONAL INSTITUTES OF HEALTH
Bethesda, MD, United States
Disclosure(s): AstraZeneca: Grant/Research Support (Ongoing); Hope Pharmaceuticals: Grant/Research Support (Ongoing)
Juvenile dermatomyositis is a rare, autoimmune illness associated with muscle weakness and typical rashes. One of the most important and difficult to manage complications is calcinosis. Calcinosis is associated with pain, disfigurement, and can be significantly debilitating. The goal of this session will be to review the current state of knowledge concerning pathogenesis, evaluation, and treatment of this problem.
Speaker: Christian Lood, PhD – University of Washington
Speaker: Adam Schiffenbauer, MD – NATIONAL INSTITUTES OF HEALTH
Speaker: Clarissa Pilkington, MBBS, BSc, FRCPC, FRCP – Great Ormond Street Hospital